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Therapeutic Misconception
 An unfounded belief held

by a research participant
that he or she will be
receiving personalized
care. Often accompanied
by an unrealistic
expectation of benefit.

Research vs Practice
 Practice
 Goal is to further the best interest of the individual patient.
 Patient-centered care, tailored to the individual.

 Research
 Goal is to generate new knowledge that may benefit future

patients.

 Protocol-driven care with little flexibility, designed to produce

interpretable data and generalizable knowledge.

Origin of TM
 Fundamentally, a confusion between research and practice.
 Both doctors (investigators) and patients (participants) are

susceptible.

Therapeutic Misconception in
participants
 Prevalence
 31% expressed inaccurate beliefs regarding degree of

individualization of their treatment.
 51% expressed an unreasonable belief in the nature or
likelihood of benefit.
 Overall, 62% had one or both of the above.

Applebaum, PS 2004, IRB: Ethics and Human Research 26:1

Why worry about TM?
 Participants that harbor TM

are likely to:

 Overestimate likely benefit
 Underestimate risks
 Be confused about

randomization
 Conflate research with
ordinary treatment

Therapeutic Misdirection
 Physicians as “double agents”
 Competing obligations that sometimes conflict
 Physician: primary obligation is to the patient
 Investigator: primary obligation is to the research

What is Therapeutic Misdirection?
 Actions taken by an investigator to try and reconcile the

competing obligations of clinical medicine with clinical
research.
 Attempt to deliver personalized care in the context of a

research protocol

 Often requires deviating from the protocol

 Promotes patient-participant TM
 May compromise scientific validity of the study

WU protocol exception requests
 Examined all protocol exception in eIRB 2008-2011
 Classified into one of 7 categories
 Analyzed
 Exception type
 Department of requestor
 Funding
 Frequency per protocol
 Types of protocols
 Frequency per investigator

Exception classifications
Exception type
Entry criteria

Description
Enrolling subjects that are ineligible according to inclusion/exclusion
criteria
Other entry
enrolling subjects that would not otherwise be permitted to enroll,
but not due to ineligibility according to I/E criteria
Example:
•
Enrolling a non-english speaking person in a study not
approved for non-english speaking persons
•
Utilizing an LAR for a study not approved to enroll cognitively
impaired subjects.
Out of window-testing
Performing a test, either for enrollment purposes or during the trial,
outside the protocol specified time window
Out of windowperforming a treatment or intervention (other than diagnostic
treatment
testing) outside of the protocol specified time window
Treatment participation altering a treatment intervention outside of what is in the approved
exception
protocol
Examples:
•
Changing drug dosing or delivery
•
holding a drug,
•
Allowing a subject to continue treatment despite lab value
that specifies holding treatment.
Testing participation
altering a research test intervention outside of what is in the
exception
approved protocol
Examples:
•
not performing a scan or diagnostic test that is prescribed in
the protocol.
Other changes to conduct of the study, that occur to the subject
Other participation
exception:
once already enrolled in the study, but not captured in above
categories

Results
 1509 open protocols being conducted by 439 Principal

Investigators during time period examined.
 106 PI’s requested 312 exceptions in 177 separate protocols
 11% of open protocols had an exception request
 24% of Investigators requested at least 1 exception

Distribution of exception types

Frequency of exceptions and open
protocols by Department

Does funding matter?

Frequency of exceptions per PI
Number of

Number of

Investigators

exception requests

53

1

18

2

15

3

5

4

3

5

3

6

1

7

2

8

1

9

1

10

1

12

1

15

1

18

1

38

Exception frequency per protocol
Number of Studies

Number of exception
requests

119

1

25

2

15

3

5

4

5

5

6

6

1

7

1

10

 10 exceptions for 1 protocol
 Phase 1 hematologic malignancy trial





Eligibility criteria – 8
o Different disease
o Labs out of range
o Had prior excluded therapies
Out of window test-1
Other participation exception – 1

 Reasons given by PI
 “enable patient to receive treatment”
 “combination treatment will offer patient a better outcome”

Phase 1 trials
 Overall Efficacy
 CR+PR= 10.6%
 CR=3.1%, PR=7.5%, SD + <PR=34.1%

 Overall toxicity
 Deaths 0.49%
 Grade 4 toxicity 14.3%

Horstmann et al, 2005 NEJM 352:9

 Phase 1 trials
 50 protocols (29%)
 72 exception requests (23% of total)

 Phase 2 trials
 49 protocols (28%)
 88 exception requests (28% of total)

 Phase 3 trials
 17 protocols (10%)
 21 exception requests (7% of total)

Prospect of benefit?
 Exception requests in Phase 1 trials
 38 -Eligibility criteria
 7 – Out of window-testing
 12 - Out of window-treatment
 10 - Treatment participation exception
 3 - Testing participation exception
 2 - Other participation exception

 23/38 indicated it would allow patient to have “treatment”.
 7/38 state the patient will benefit by receiving the

investigational drug.

Why?
 Competing obligations and inherent conflicts
 Are we doctors trying desperately to treat a dying patient or

investigators trying to determine if the drug is safe and
effective? Can we do both at the same time?
 Pressure to enroll and complete trials

What’s the downside?
 Effect on the science
 At best it muddies the water, at worst, invalidates the data.

 Effect on the patient-participant
 Further promotes their own therapeutic misconception.

 Effect on the investigator
 Further blurs the distinction between roles and obligations

 Potential to effect overall risk/benefit analysis of the study.

Conclusions
 Requests to deviate from the approved protocol are relatively

frequent among protocols and investigators

 Protocol deviations are a reasonable way to measure therapeutic

misdirection

 Exceptions are not limited to trials in which the drug has

evidence of safety and efficacy.
 Physician expectation of benefit is common in requesting an
exception
 Physicians attempt to use established trials as a mechanism
for “expanded access”
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